AI Personalized Vaccine Design Platform VaccineForge Approved by EMA: Custom mRNA Vaccines From Pathogen Genome in Just 7 Days
BioNTech's AI personalized vaccine design platform VaccineForge gains EMA conditional approval, designing candidate mRNA vaccine sequences from pathogen genome in just 7 days, with effectiveness validated in flu variant vaccines.
On January 20, 2030, BioNTech announced its AI personalized vaccine design platform VaccineForge received EMA conditional approval. The platform can complete candidate mRNA vaccine design from pathogen genome sequences in 7 days, reducing traditional vaccine development timelines from months to one week.
In clinical trials against H3N2 flu variants, VaccineForge designed a vaccine from genome analysis to clinical trial vaccine in just 9 days versus the traditional 4 to 6 months, with 78% efficacy. BioNTech CEO Ugur Sahin said VaccineForge's true value lies in pandemic response — providing candidate vaccines within one week of a new pathogen emergence.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.